LXEO — Lexeo Therapeutics, Inc. Common Stock stock price, charts and financials
QT17Lexeo Therapeutics, Inc. Common StockLexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
4.18
+0.02+0.48%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 11.45% | Shs Outstand | 78.52M | Perf Week | -4.13% |
| Market Cap | 328.22M | Forward P/E | - | EPS next Y | -1.37 | Insider Trans | -1.40% | Shs Float | 47.42M | Perf Month | -15.21% |
| Enterprise Value | 120.22M | PEG | - | EPS next Q | -0.33 | Inst Own | - | Short Float | 43.20% | Perf Quarter | -16.06% |
| Income | -100.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 21.85 | Perf Half Y | -27.43% |
| Sales | 0.00 | P/B | 1.40 | EPS next Y | -12.42% | ROA | -34.24% | Short Interest | 20.49M | Perf YTD | -57.91% |
| Book/sh | 2.99 | P/C | 1.55 | EPS next 5Y | - | ROE | -41.85% | 52W High | 10.99 -61.97% | Perf Year | -19.77% |
| Cash/sh | 2.70 | P/FCF | - | EPS past 3/5Y | - | ROIC | -39.33% | 52W Low | 3.99 4.76% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.11% 5.22% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 62.78% | Oper. Margin | 0.00% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.89 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 35.59 | Recom | 1.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.89 | EPS Q/Q | 50.00% | SMA20 | -10.44% | Beta | 1.72 | Target Price | 21.13 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | -10.43% | Rel Volume | 1.21 | Prev Close | 4.16 |
| Employees | 63 | LT Debt/Eq | 0.02 | Earnings | Dec 14 | SMA200 | -32.48% | Avg Volume | 909.98K | Price | 4.18 |
| IPO Date | Nov 03, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -5.20% - | Net Debt/EBITDA | 1.01 | Volume | 1,099,053 | Change | 0.48% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-13-26 | Reiterated | HC Wainwright & Co. | Buy | $13 → $10 |
| Dec-17-25 | Initiated | Raymond James | Strong Buy | |
| Dec-10-25 | Reiterated | Oppenheimer | ||
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight | |
| Oct-21-25 | Reiterated | HC Wainwright & Co. | Buy | $15 → $13 |
| Oct-15-25 | Initiated | Guggenheim | Buy | |
| Oct-07-25 | Reiterated | Leerink Partners | Outperform | |
| Oct-07-25 | Reiterated | HC Wainwright & Co. | Buy | $15 |
| Oct-07-25 | Reiterated | Chardan Capital | Buy | |
| Jun-12-24 | Initiated | Baird | Outperform |
Latest News· Times ET
Sep-02-26
03:00AM
Aug-26-26
Aug-26-2611:55PM
Aug-12-26
03:00AM
Aug-05-26
Aug-05-2603:00AM
Jul-27-26
Jul-10-26
Jul-10-2604:03AM
Jun-30-26
Jun-30-2601:32PM
Jun-25-26
Jun-25-2606:54AM
Jun-22-26
Jun-22-2604:30AM
Jun-17-26
Jun-17-2612:04PM
Jun-15-26
09:01AM
07:32AM
Company
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 45 | 32 | 15 | — | — | — | |
| Research and Development | 64 | 74 | 53 | — | — | — | |
| Other Operating Expense | 0 | 0 | 1 | — | — | — | |
| Operating Income | -109 | -106 | -69 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 8 | 2 | — | — | — | |
| Net Income Before Taxes | -100 | -98 | -66 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -100 | -98 | -66 | — | — | — | |
| Net Income From Continuing Operations | -100 | -98 | -66 | — | — | — | |
| Net Income | -100 | -98 | -66 | — | — | — | |
| EPS (Recurring) | -1.86 | -3.09 | -2.49 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.86 | -3.09 | -2.49 | — | — | — | |
| EPS (Diluted) | -1.86 | -3.09 | -2.49 | — | — | — | |
| EBITDA | -98 | -96 | -64 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 54 | 32 | 27 | — | — | — | |
| Market Capitalization | 536 | 211 | 362 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Tamayo Louis Edward | Chief Financial Officer | Aug 18 '26 | Sale | 4.91 | 4,117 | 20,203 | 92,907 | Aug 19 |
| Townsend Richard Nolan | Chief Executive Officer | Aug 18 '26 | Sale | 4.95 | 3,345 | 16,562 | 374,472 | Aug 19 |
| Otero Jose Manuel | Chief Operating Officer | Aug 18 '26 | Sale | 4.96 | 1,304 | 6,464 | 136,178 | Aug 19 |
| Townsend Richard Nolan | Chief Executive Officer | Jul 01 '26 | Sale | 4.48 | 25,947 | 116,243 | 377,817 | Jul 01 |
| Tamayo Louis Edward | Chief Financial Officer | Jul 01 '26 | Sale | 4.49 | 4,641 | 20,838 | 97,024 | Jul 01 |
| Otero Jose Manuel | Chief Operating Officer | Jul 01 '26 | Sale | 4.48 | 4,666 | 20,904 | 137,482 | Jul 01 |
| Bhalla Narinder Pal | Chief Medical Officer | Jul 01 '26 | Sale | 4.42 | 22,306 | 98,593 | 82,194 | Jul 01 |
| Otero Jose Manuel | Chief Operating Officer | May 18 '26 | Sale | 5.07 | 1,302 | 6,606 | 130,088 | May 20 |
| Townsend Richard Nolan | Chief Executive Officer | May 18 '26 | Sale | 5.06 | 3,342 | 16,927 | 336,764 | May 20 |
| Townsend Richard Nolan | Chief Executive Officer | Apr 06 '26 | Sale | 5.69 | 55,000 | 313,137 | 340,106 | Apr 07 |
| Otero Jose Manuel | Chief Operating Officer | Feb 18 '26 | Sale | 6.40 | 3,016 | 19,294 | 125,460 | Feb 20 |
| Townsend Richard Nolan | Chief Executive Officer | Feb 18 '26 | Sale | 6.38 | 10,173 | 64,924 | 392,483 | Feb 20 |
| Otero Jose Manuel | Chief Operating Officer | Nov 18 '25 | Sale | 9.27 | 721 | 6,684 | 63,476 | Feb 20 |
| See Tai Sandi | Chief Development Officer | Nov 18 '25 | Sale | 9.27 | 386 | 3,578 | 65,476 | Nov 20 |
| Townsend Richard Nolan | Chief Executive Officer | Nov 18 '25 | Sale | 9.27 | 1,127 | 10,447 | 240,991 | Nov 20 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.